Back to News
Market Impact: 0.35
Lisata Therapeutics Acquires Marea Therapeutics; Announces Concurrent Private Placement
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
Lisata Therapeutics acquired clinical-stage biotech Marea Therapeutics in a stock-for-stock transaction. Marea develops genetically informed therapies for cardioendocrine diseases, expanding Lisata's clinical-stage pipeline; the article excerpt did not disclose transaction value, exchange terms, or expected financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LSTA0.65
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- People Inc earnings up next after MGM deal collapse
- Mizuho raises Dominion Energy stock price target to $68 on earnings beat
- Wells Fargo raises Abbvie stock price target to $340 on pipeline